MOUNTAIN VIEW, Calif.,
March 15, 2016 /PRNewswire/
-- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) will report
results for its fiscal quarter and year ended December 31, 2015 on Monday, March 28, 2016 following the close of the
U.S. financial markets. The Company will also host an
investor conference call and live webcast on the same day at
5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time to provide a company
update and discuss the financial results.
To access the webcast via the Internet, go to www.alexza.com,
under the "Investors" link. Please log onto the webcast prior
to the start of the call to ensure time for any software downloads
that may be required to participate in the webcast.
LIVE CALL:
1-844-492-3732 or +1-412-542-4199
(international)
Passcode: Please ask to be joined into the Alexza
Pharmaceuticals call
REPLAY:
1-877-344-7529 or +1-412-317-0088
(international)
Passcode: 10082706
A replay of the conference call may also be accessed at
www.alexza.com under the "Investors" link. A replay of the
call will be available for 7 days following the conference
call.
About Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals is focused on the research, development, and
commercialization of novel, proprietary products for the acute
treatment of central nervous system conditions. Alexza's
products and development pipeline are based on the
Staccato® system, a hand-held inhaler designed to
deliver a pure drug aerosol to the deep lung, providing rapid
systemic delivery and therapeutic onset, in a simple, non-invasive
manner. Active pipeline product candidates include AZ-002
(Staccato alprazolam) for the management of epilepsy in
patients with acute repetitive seizures and AZ-007 (Staccato
zaleplon) for the treatment of patients with middle of the night
insomnia.
ADASUVE® is Alexza's first commercial product and is
currently available in 20 countries. The product is approved
for sale by the U.S. Food and Drug Administration, the European
Commission and in several Latin American countries. Grupo
Ferrer Internacional SA is Alexza's commercial partner for ADASUVE
in Europe, Latin America, the Commonwealth of Independent
States countries, the Middle East
and North Africa countries, Korea,
Philippines and Thailand.
ADASUVE® and Staccato® are registered
trademarks of Alexza Pharmaceuticals, Inc. For more
information about Alexza, the Staccato system technology or
the Company's development programs, please visit
www.alexza.com.
Safe Harbor Statement
The anticipated news release and conference call will contain
forward-looking statements that involve significant risks and
uncertainties. Any statement describing the Company's expectations
or beliefs is a forward-looking statement, as defined in the
Private Securities Litigation Reform Act of 1995, and should be
considered an at-risk statement. Such statements are subject to
certain risks and uncertainties, particularly those inherent in the
process of developing and commercializing drugs, including the
adequacy of the Company's capital to support the Company's
operations, the ability of Alexza and Ferrer to effectively and
profitably commercialize ADASUVE, Alexza's ability to secure a new
U.S. commercial partner for ADASUVE and the terms of any such
partnership, estimated product revenues and royalties associated
with the sale of ADASUVE, and the Company's ability to raise
additional funds and the potential terms of such potential
financings. The Company's forward-looking statements also
involve assumptions that, if they prove incorrect, would cause its
results to differ materially from those expressed or implied by
such forward-looking statements. These and other risks concerning
Alexza's business are described in additional detail in the
Company's Annual Report on Form 10-K for the year ended
December 31, 2014 and the Company's
other Periodic and Current Reports filed with the Securities and
Exchange Commission. Forward-looking statements contained in this
announcement are made as of this date, and the Company undertakes
no obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or
otherwise.
Logo -
http://photos.prnewswire.com/prnh/20140121/SF49110LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/alexza-to-report-2015-year-end-financial-results-and-provide-company-update-on-monday-march-28-2016-300236592.html
SOURCE Alexza Pharmaceuticals, Inc.